Yahoo! FinanceFinance Home - My Yahoo - Yahoo! - Help 

Wednesday, November 25, 2009, 1:01PM ET - U.S. Markets close in 2 hours and 59 minutes. Dow Up 0.16% Nasdaq Up 0.24%
Celgene Corporation (CELG)At 12:46PM ET: 55.59  Up 0.22 (0.40%)  
MORE ON CELG
Quotes
Charts
News & Info
Company
HereProfile
Analyst Coverage
Ownership
Financials

ProfileGet Profile for:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States - Map
Phone: 908-673-9000
Web Site: http://www.celgene.com

DETAILS 
Index Membership:S&P 500
S&P 1500 Super Comp
Nasdaq 100
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:2,441

BUSINESS SUMMARY 
Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum. The company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer. The company was founded in 1980 and is headquartered in Summit, New Jersey.
Key Statistics

COMPANY WEBSITES 
  • Home Page
  • Search Yahoo! for:
    More on Celgene Corporation


    CORPORATE GOVERNANCE 
    Celgene Corporation's Corporate Governance Quotient (CGQ®) as of 6-Nov-09 is better than 21.6% of S&P 500 companies and 88.7% of Pharmaceuticals, Biotechnology & Life Sciences companies.
    Brought to you by Institutional Shareholder Services.

    KEY EXECUTIVES 
     PayExercised
    Dr. Sol J. Barer Ph.D., 62
    Exec. Chairman, Chief Exec. Officer and Chairman of Exec. Committee
    $ 3.11M $ 55.97M
    Mr. Robert J. Hugin MBA, 54
    Pres, Chief Operating Officer, Sec.
    $ 2.31M $ 72.15M
    Mr. David W. Gryska , 52
    Chief Financial Officer and Sr. VP
    $ 840.00K $ 160.00K
    Mr. Aart Brouwer , 68
    Pres of International
    $ 1.32M $ 0
    Dr. Graham Burton MBBS, FRCP, 58
    Sr. VP Global Regulatory Affairs &Pharmacovigilance & Corp. Compliance
    $ 1.03M $ 7.27M
    Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
    View Insiders


    Add to My Portfolio Add to Portfolio    Set Alert Set Alert    Email to a Friend Email to a Friend
    Get Profile for Another Symbol: Symbol Lookup
    Annual ReportsSector Analysis